




(86) Date de dépôt PCT/PCT Filing Date: 1999/08/12  
(87) Date publication PCT/PCT Publication Date: 2000/03/02  
(45) Date de délivrance/Issue Date: 2006/04/04  
(85) Entrée phase nationale/National Entry: 2001/02/16  
(86) N° demande PCT/PCT Application No.: EP 1999/005928  
(87) N° publication PCT/PCT Publication No.: 2000/010995  
(30) Priorité/Priority: 1998/08/18 (198 43 413.8) DE

(51) Cl.Int./Int.Cl. *C07D 401/12* (2006.01),  
*A61K 31/4439* (2006.01)  
(72) Inventeur/Inventor:  
KOHL, BERNHARD, DE  
(73) Propriétaire/Owner:  
ALTANA PHARMA AG, DE  
(74) Agent: GOWLING LAFLEUR HENDERSON LLP

(54) Titre : FORME DE SEL DE PANTOPRAZOLE  
(54) Title: NOVEL SALT FORM OF PANTOPRAZOLE




(57) Abrégé/Abstract:

The invention relates to the dihydrate of the magnesium salt of pantoprazole. Pantoprazole has the following chemical structure: (see above formula). The novel compound (also referred to as pantoprazole magnesium dihydrate) is useful for the treatment and prevention of diseases which are considered to be treatable or avoidable by the use of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. In particular, the novel compound can be employed in the treatment of disorders of the stomach or the intestine.



ABSTRACT OF THE DISCLOSURE

The invention relates to the dihydrate of the magnesium salt of pantoprazole. Pantoprazole has the following chemical structure:



The novel compound (also referred to as pantoprazole magnesium dihydrate) is useful for the treatment and prevention of diseases which are considered to be treatable or avoidable by the use of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. In particular, the novel compound can be employed in the treatment of disorders of the stomach or the intestine.

**Novel salt form of pantoprazole****Subject of the invention**

The present invention relates to a novel salt form of the active compound pantoprazole. The novel salt form can be employed in the pharmaceutical industry for the preparation of medicaments.

**Prior art**

Pyridin-2-ylmethylsulfinyl-1H-benzimidazoles, such as are disclosed, for example, in EP-A-0005129, EP-A-0166287, EP-A-0174726 and EP-A-0268956, have, on account of their H<sup>+</sup>/K<sup>+</sup> ATPase-inhibiting action, considerable importance in the therapy of diseases which are due to increased gastric acid secretion. Examples of commercially available active compounds from this group are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: omeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: lansoprazole) and 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (INN: rabeprazole).

A common property of the abovementioned pyridin-2-ylmethylsulfinyl-1H-benzimidazoles is the acid sensitivity - which is in the end indispensable for their efficacy - of these active compounds, which is seen in their strong tendency to decompose in a neutral and, in particular, acidic environment, strongly colored decomposition products being formed.

In the past, there have been considerable efforts, despite the acid sensitivity of the pyridin-2-ylmethylsulfinyl-1H-benzimidazoles, to obtain stable and storable oral administration forms which contain these pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. Such stable and storable oral administration forms (e.g. tablets or capsules) are now obtainable. The preparation of these oral administration forms, however, is comparatively complicated and also certain precautions must be taken with respect to the packaging, in order that the administration forms have an adequate storage stability even under extreme storage conditions (e.g. in the tropics at high temperature and high atmospheric humidity).

The International Patent Application WO97/41114 describes a specific process for the preparation of magnesium salts of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. Inter alia, the preparation of the magnesium salt of pantoprazole is also described by way of example. According to the analysis data indicated, the salt prepared is pantoprazole magnesium in anhydrous form.

**Description of the invention**

It has now been found that the dihydrate of the magnesium salt of pantoprazole has very surprising stability properties which make it appear to be particularly suitable for use in solid or oral administration forms. It exhibits very considerably improved stability properties both in comparison with pantoprazole itself and in comparison to pantoprazole sodium sesquihydrate (the active compound form on the market since 1994, European Patent 0 589 981), or in comparison to pantoprazole sodium monohydrate (the intermediate form used in the industrial preparation, European Patent 0 533 790).

Thus pantoprazole magnesium dihydrate is completely stable for 4 days at 90°C and exhibits almost no discoloration or decomposition, while pantoprazole sodium sesquihydrate and monohydrate turn brown-red in the same period with formation of considerable amounts of decomposition products.

The invention thus relates to the dihydrate of the magnesium salt of pantoprazole (pantoprazole magnesium dihydrate).

Pantoprazole magnesium dihydrate can be employed for the treatment and prevention of all the diseases which are considered to be treatable or avoidable by the use of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. In particular, pantoprazole magnesium dihydrate can be employed in the treatment of disorders of the stomach or intestine.

On account of its solubility properties, possibilities of application for pantoprazole magnesium dihydrate are conceivable for whose realization resort had to be made up to now to particular pharmaceutical preparations. Thus use of pantoprazole magnesium dihydrate is particularly suitable, inter alia, where the active compound is to be released and absorbed over a relatively long period (see, for example, European Patent Application 0 841 903). By means of a combination of the magnesium salt of pantoprazole with the sodium salt, a solution made to order for certain desired active compound blood level courses can be achieved.

The pantoprazole magnesium dihydrate is prepared in a manner known per se by reaction of pantoprazole or a readily soluble pantoprazole salt (e.g. pantoprazole sodium) with a magnesium salt in water or in mixtures of water with polar organic solvents (e.g. alcohols, preferably ethanol or isopropanol, or ketones, for example acetone or butanone).

Suitable magnesium salts which can be employed according to the process are, for example, magnesium chloride, bromide, fluoride, iodide, formate, acetate, propionate, sulfate, gluconate or carbonate. Alkoxides of magnesium (e.g. magnesium methoxide, ethoxide, (iso)propoxide, butoxide, hexoxide or phenoxide), or magnesium hydroxide can also be reacted with pantoprazole or pantoprazole sodium in aqueous medium.

**Example****Magnesium bis[5-[difluoromethoxy]-2-[[3,4-dimethoxy-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazolide] dihydrate**

3.85 kg (8.9 mol) of pantoprazole Na sesquihydrate [sodium [5-[difluoromethoxy]-2-[[3,4-dimethoxy-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazolide]sesquihydrate] are dissolved at 20-25°C in 38.5 l of purified water in a stirring vessel. A solution of 1.0 kg (4.90 mol) of magnesium dichloride hexahydrate in 8 l of purified water is added with stirring at 20-30°C in the course of 3 to 4 h. After stirring for a further 18 h, the precipitated solid is centrifuged, washed with 23 l of purified water, stirred at 20-30°C for 1 to 2 h in 35 l of purified water, centrifuged again and washed again with 30-50 l of purified water. The solid product is dried at 50°C in vacuo (30-50 mbar) until a residual water content of < 4.8% is achieved. The product is then ground.

The title compound is obtained as a white to beige powder, which is employed directly for further pharmaceutical processing.

Yield: 3.40 kg (90% of theory); water content: 4.5-4.6%; melting point: 194-196°C with decomposition.

CHN analysis	C	H	N	S
Theory	46.58	3.91	10.19	7.77
Found	46.33	3.89	10.04	7.83

Alternatively the title compound can be produced using mixtures of organic solvents with water. For this, pantoprazole Na sesquihydrate is dissolved in an organic solvent at 50-60°C. 0.5 mole equivalents of the magnesium salt (e. g. magnesium chloride hexahydrate), dissolved in water, are added drop by drop and the solution is allowed to cool with stirring. The precipitated solid is filtered off, washed with the corresponding organic solvent and is dried in vacuo at 50°C to constant weight. The title compound is obtained as a colourless powder. Examples for different solvents are given in the following table 1.

Table 1:

pantoprazole Na sesquihydrate	organic solvent	water	yield of title compound	melting point ° C	water content %
50 g	isopropanol 300 ml	300 ml	45,4 g	196 – 197	4,4 – 4,5
50 g	isopropanol 300 ml	120 ml	45,9 g	196 – 197	4,3

pantoprazole Na ses- quihydrate	organic solvent	water	yield of title com- pound	melting point ° C	water content %
50 g	ethanol 300 ml	300 ml	45,8 g	197 - 198	4,6
50 g	aceton 300 ml	300 ml	45,6 g	195 - 196	4,6, - 4,7

Alternatively the title compound can be produced by reacting pantoprazole with a basic magnesium salt, such as magnesium methylate, for example in the following manner: 90 g of pantoprazole are dissolved in 700 ml of 2-propanol at 60-70°C. 13.4 g (0.5 moles) of solid magnesium methylate are added, the solution is allowed to cool with stirring and filtered. After addition of 36 ml of water the crystalline solid formed is filtered off, washed with water and dried in vacuo at 50°C to constant weight. The title compound of melting point 194-196°C (water content 4.8 %) is obtained as beige solid.

What is claimed is:

1. Pantoprazole magnesium dihydrate.
2. A pharmaceutical composition comprising pantoprazole magnesium dihydrate, together with an auxiliary.
3. A pharmaceutical composition comprising a combination of pantoprazole magnesium dihydrate and pantoprazole sodium sesquihydrate.
4. A pharmaceutical composition comprising a combination of pantoprazole magnesium dihydrate and pantoprazole sodium sesquihydrate in the weight ratio (based on pantoprazole) of 10% pantoprazole magnesium dihydrate and 90% pantoprazole sodium sesquihydrate to 90% pantoprazole magnesium dihydrate and 10% pantoprazole sodium sesquihydrate.
5. A pharmaceutical composition comprising a combination of pantoprazole magnesium dihydrate and pantoprazole sodium sesquihydrate in the weight ratio (based on pantoprazole) of 25% pantoprazole magnesium dihydrate and 75% pantoprazole sodium sesquihydrate to 75% pantoprazole magnesium dihydrate and 25% pantoprazole sodium sesquihydrate.
6. A pharmaceutical composition comprising a combination of pantoprazole magnesium dihydrate and pantoprazole sodium sesquihydrate in the weight ratio (based on pantoprazole) of 40% pantoprazole magnesium dihydrate and 60% pantoprazole sodium sesquihydrate to 60% pantoprazole magnesium dihydrate and 40% pantoprazole sodium sesquihydrate.
7. A pharmaceutical composition comprising a combination of pantoprazole magnesium dihydrate and pantoprazole sodium sesquihydrate in the weight ratio (based on pantoprazole) of 50% pantoprazole magnesium dihydrate and 50% pantoprazole sodium sesquihydrate.
8. The pharmaceutical composition defined in any one of Claims 2-7, in solid administration form.

9. The pharmaceutical composition defined in any one of Claims 2-7, in oral administration form.
10. Use of pantoprazole magnesium dihydrate to treat a stomach disorder.
11. A stomach disorder treatment composition comprising pantoprazole magnesium dihydrate, together with an auxiliary therefor.
12. Use of pantoprazole magnesium dihydrate to treat an intestinal disorder.
13. An intestinal disorder treatment composition comprising pantoprazole magnesium dihydrate, together with an auxiliary therefor.
14. Use of pantoprazole magnesium dihydrate to treat a disease due to increased gastric acid.
15. A gastric acid mediated disease treatment composition comprising pantoprazole magnesium dihydrate, together with an auxiliary therefor.
16. Use of pantoprazole magnesium dihydrate to prevent a disease due to increased gastric acid.
17. A gastric acid mediated disease prevention composition comprising pantoprazole magnesium dihydrate, together with an auxiliary therefor.
18. Use of the pharmaceutical composition defined in any one of Claims 2-9 to treat a stomach disorder.
19. Use of the pharmaceutical composition defined in any one of Claims 2-9 to treat an intestinal disorder.
20. Use of the pharmaceutical composition defined in any one of Claims 2-9 to treat a disease due to increased gastric acid.



21. Use of the pharmaceutical composition defined in any one of Claims 2-9 to prevent a disease due to increased gastric acid.
22. A process for producing pantoprazole magnesium dihydrate comprising the step of reacting pantoprazole or a readily soluble pantoprazole salt with a magnesium salt in an aqueous solvent.
23. The process defined in Claim 22, wherein the readily soluble pantoprazole salt comprises pantoprazole sodium.
24. The process defined in any one of Claims 22-23, wherein the solvent comprises water.
25. The process defined in any one of Claims 22-23, wherein the solvent comprises a mixture of water and a polar organic solvent.
26. The process defined in Claim 25, wherein the polar organic solvent comprises an alcohol.
27. The process defined in Claim 26, wherein the alcohol comprises ethanol.
28. The process defined in Claim 26, wherein the alcohol comprises isopropanol.
29. The process defined in Claim 25, wherein the polar organic solvent comprises a ketone.
30. The process defined in Claim 29, wherein the ketone comprises acetone.
31. The process defined in Claim 29, wherein the ketone comprises butanone.
32. The process defined in any one of Claims 22-31, wherein the magnesium salt is selected from the group comprising magnesium chloride, magnesium bromide, magnesium fluoride, magnesium iodide, magnesium formate, magnesium acetate, magnesium propionate, magnesium sulfate, magnesium gluconate and magnesium carbonate.

33. The process defined in any one of Claims 22-31, wherein the magnesium salt comprises a magnesium alkoxide.

34. The process defined in Claim 33, wherein the magnesium alkoxide is selected from the group comprising magnesium methoxide, magnesium ethoxide, magnesium (iso)propoxide, magnesium butoxide, magnesium hexoxide and magnesium phenoxide.

35. The process defined in any one of Claims 22-31, wherein the magnesium salt comprises a magnesium hydroxide.

36. Pantoprazole magnesium dihydrate produced according to the process defined in any one of Claims 22-35.

